BioSpace News Archive

STAAR Surgical Company today reported preliminary sales for the fourth quarter and fiscal year ended December 30, 2022.

BT BeaMedical Technologies (“BeaMed”), a private company minority-owned by Innovation Pharmaceuticals (OTC: IPIX) (the “Company”) developing a next-generation laser based platform for epilepsy and cancer surgery, has notified the Company that it has entered into a definitive strategic agreement with Shina Systems Ltd.

HilleVax, Inc. announced the appointment of Ozzie Berger as Senior Vice President of Regulatory Affairs, the promotion of Anju Chatterji to Chief Technical Officer, and the promotion of Shane Maltbie to Chief Financial Officer.

TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, announced the commercial launch of its NIVIS Fibrillar Collagen Pack.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, provided an update on the company’s clinical development programs for 2023, including its strategic priorities and expectations for achievement of a variety of milestones.

Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the enrollment of the first subject in a Phase 1 proof-of-concept study of TRV045, a novel sphingosine-1-phosphate receptor modulator selective for the S1P receptor subtype 1.

Shattuck Labs, Inc. provided a corporate update and highlighted upcoming key milestones anticipated in 2023.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced preliminary, unaudited ORLADEYO® (berotralstat) net revenue for the fourth quarter and full year 2022 and provided guidance for full year 2023 ORLADEYO net revenue and expected peak ORLADEYO sales.

Amicus Therapeutics today provided its preliminary and unaudited 2022 revenue, corporate updates, and full-year 2023 outlook.

Ractigen Therapeutics, Inc. announced today that Dr. Harri Järveläinen has been appointed Chief Operating Officer of the Company.